Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

Leukemia volume 25, pages 1904–1908 (2011)Cite this article

Subjects

Mutation of the TP53 gene at chromosome band 17p13 is the single most common genetic alteration found in human cancer, although the prevalence of TP53 mutations is considerably lower in hematological malignancies (<20%) compared with solid tumors (>50%).1 Nevertheless, TP53 mutations have been reported to be associated with poor prognosis in hematological malignancies, such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).1 Furthermore, the profile of TP53 mutations appears to vary between different cancers, and a relationship has been found between certain carcinogens and specific mutation types.2

Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma characterized by the t(11;14)(q13;q32), leading to cyclin D1 overexpression. MCL displays a high degree of genomic instability, reflected by a large number of secondary aberrations, and has an average survival of only 4–5 years.3 However, the TP53 gene, which is an essential gene for genomic integrity, has not been extensively studied in MCL, although TP53 mutations have been reported more frequently in the clinically aggressive blastoid variant.1 In one of the larger reports from the Leukemia and Lymphoma Molecular Profiling Project (LLMPP), TP53 mutations were found in 16/82 (20%) of MCL samples and were associated with an unfavorable clinical course.4 That notwithstanding, the prognostic relevance of 17p deletions (which include the TP53 gene) in MCL is less clear, although several studies have indicated an association with short survival.5

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Cheung KJ, Horsman DE, Gascoyne RD . The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009; 146: 257–269.

    Article  CAS  PubMed  Google Scholar 

  2. Soussi T, Wiman KG . Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303–312.

    Article  CAS  PubMed  Google Scholar 

  3. Halldorsdottir AM, Sander B, Goransson H, Isaksson A, Kimby E, Mansouri M et al. High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 2010; 50: 113–121.

    Article  Google Scholar 

  4. Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103: 2352–2357.

    Article  CAS  PubMed  Google Scholar 

  5. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105: 4445–4454.

    Article  CAS  PubMed  Google Scholar 

  6. Swerdlow SH, Campo E, Seto M, Müller-Hermelink HK . Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th edn, vol. 2. World Health Organization: Lyon, France, 2008, pp 229–232.

    Google Scholar 

  7. Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011; 35: 272–274.

    Article  CAS  PubMed  Google Scholar 

  8. Flordal Thelander E, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007; 31: 1219–1230.

    Article  CAS  PubMed  Google Scholar 

  9. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116: 953–961.

    Article  CAS  PubMed  Google Scholar 

  10. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302–4310.

    CAS  PubMed  Google Scholar 

  11. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351–3359.

    CAS  PubMed  Google Scholar 

  12. Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.

    Article  PubMed  Google Scholar 

  13. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010; 24: 2072–2079.

    Article  CAS  PubMed  Google Scholar 

  14. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93: 4365–4374.

    CAS  PubMed  Google Scholar 

  15. Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007; 25: 1216–1222.

    Article  CAS  PubMed  Google Scholar 

  16. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329.

    Article  CAS  PubMed  Google Scholar 

  17. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088–3098.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by Swedish Cancer Society and the Swedish Research Council. The authors wish to acknowledge Drs Tor Olofsson, Mats Jerkeman, Mats Ehinger, Michael Dictor, Anna Porwit, Erik Björck, Göran Roos, Ola Landgren for providing samples and associated data, and to Drs Svetlana Lagercrantz and Emma Flordal Thelander for contributing molecular data.

Author information

Authors and Affiliations

  1. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

    A M Halldórsdóttir, A Lundin, F Murray, L Mansouri, C Sundström & R Rosenquist

  2. Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland

    S Knuutila

  3. Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

    A Laurell

  4. Department of Clinical Genetics, Lund University Hospital, Lund, Sweden

    H Ehrencrona

  5. Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Huddinge, Sweden

    B Sander

Authors
  1. A M Halldórsdóttir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Lundin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Mansouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Knuutila
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Sundström
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Laurell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Ehrencrona
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Rosenquist
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Rosenquist.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halldórsdóttir, A., Lundin, A., Murray, F. et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 25, 1904–1908 (2011). https://doi.org/10.1038/leu.2011.162

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.162

This article is cited by

Search

Advanced search

Quick links